Showing results (241-250 of 781) with videos related to
Sort By:
Pageof 79
Molecular Cancer Therapeutics|April 14, 2005
Proteasome inhibitor therapy in multiple myelomaDharminder Chauhan, Teru Hideshima, Constantine Mitsiades, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Proteasome inhibition as a novel therapeutic target in human cancerS Vincent Rajkumar, Paul G Richardson, Teru Hideshima, et al.Oncogene|February 7, 2020
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.Blood Advances|October 10, 2019
The impact of response kinetics for multiple myeloma in the era of novel agentsYuting Yan, Xuehan Mao, Jiahui Liu, et al.Leukemia & Lymphoma|May 3, 2008
Thalidomide and lenalidomide: Mechanism-based potential drug combinationsSonia Vallet, Antonio Palumbo, Noopur Raje, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Individualizing treatment of patients with myeloma in the era of novel agentsJesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, et al.Leukemia|May 20, 2020
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13Ting Du, Yan Song, Arghya Ray, et al.Oncology (Williston Park, N.Y.)|April 2, 2014
The heavy chain diseases: clinical and pathologic featuresGiada Bianchi, Kenneth C Anderson, Nancy Lee Harris, et al.Nature Reviews. Clinical Oncology|November 26, 2014
Current treatment landscape for relapsed and/or refractory multiple myelomaMeletios A Dimopoulos, Paul G Richardson, Philippe Moreau, et al.Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.Pageof 79